Moody's Corporation vs Tempus AI — how do they compare? Moody's Corporation trades at $458.7 (market cap $79.44B), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Moody's Corporation is far larger — about 6.3× Tempus AI's market cap, and Moody's Corporation pays a 0.9% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Tempus AI for 22 Days on average.
| MCO | TEM | |
|---|---|---|
Market Cap | $79.44B | $12.58B |
Volume | 526,684 | 7,444,569 |
Sector | Financials | Broad Market / Factor |
52-Week High | $539.61 | $99.28 |
52-Week Low | $412.23 | $41.55 |
Typical Hold Time | 132 Days | 22 Days |
Enterprise Value | $85.46B | $13.21B |
Dividend Yield | 0.9% | — |
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $449.63, down 0.59% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, while net income margins expanded to 34.25%. Recent developments include strategic partnerships and board appointments, supporting the company's market leadership in credit analytics.
The investment outlook is positive given Moody's robust profitability, high ROE of 80.15%, and analyst consensus price target of $536.40 (19% upside). Risks include high valuation multiples (P/E 28.53, P/S 9.79) and exposure to economic cycles affecting credit demand. Institutional sentiment remains bullish with 56% buy ratings, though technical indicators suggest near-term consolidation near support at $440.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →